Johnson & Johnson has the GF Score of 85, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Johnson & Johnson
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Johnson & Johnson (NYSE:JNJ) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Johnson & Johnson GF Score Related Terms
JNJ vs ABBV, MRK, AMGN: GF Score Comparison
For the Drug Manufacturers - General subindustry, Johnson & Johnson's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's GF Score distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's GF Score falls into.
Johnson & Johnson (JNJ) has a GF Score of 85 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Johnson & Johnson and its competitors. This is near median its historical median of 88.00. Over the past decade, Johnson & Johnson's GF Score has ranged from 73.00 to 96.00.
Is Johnson & Johnson's GF Score too high?
Johnson & Johnson's current GF Score of 85 is near median its 10-year median of 88.00. Over the past 10 years, this metric has ranged from a low of 73.00 to a high of 96.00. Overall, Johnson & Johnson has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's GF Score compare to ABBV and MRK?
Johnson & Johnson's GF Score of 85 can be compared against companies in the Drug Manufacturers industry. Historically, Johnson & Johnson's own GF Score has ranged from 73.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Johnson & Johnson and its competitors. Johnson & Johnson's current GF Score is 85, which is near median its own 10-year median of 88.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $190.74, compared to a current price of $253.95 — trading 33.1% above its estimated fair value. The current GF Score is 85, which is near median its 10-year median of 88.00. Johnson & Johnson's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current GF Score is 85 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of $253.95 is trading 33.1% above its estimated GF Value™ of $190.74.
GuruFocus considers Johnson & Johnson to be Significantly Overvalued.
Key valuation signals for JNJ:
GF Score: 85 (near median its 10-year median of 88.00)
GF Value™: $190.74 vs. price of $253.95 (33.1% above fair value)
No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
85GF Score
Get the complete analysis for JNJ
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNJ has been successfully added to your 